Osteosarcopenia is a significant predictor of recurrence and the prognosis after resection for extrahepatic bile duct cancer
- PMID: 37700170
- DOI: 10.1007/s00595-023-02747-0
Osteosarcopenia is a significant predictor of recurrence and the prognosis after resection for extrahepatic bile duct cancer
Abstract
Purpose: This study examined the impact of osteosarcopenia on recurrence and the prognosis after resection for extrahepatic biliary tract cancer (EBTC).
Methods: We retrospectively analyzed 138 patients after resection for perihilar cholangiocarcinoma (11), distal cholangiocarcinoma (54), gallbladder carcinoma (30), or ampullary carcinoma (43). Osteosarcopenia is defined as the concomitant occurrence of osteopenia and sarcopenia. We investigated the relationship between osteosarcopenia and the overall survival (OS) and disease-free survival (DFS) in univariate and multivariate analyses.
Results: Osteosarcopenia was identified in 38 patients (27.5%) before propensity score (PS) matching. In the multivariate analysis, the independent recurrence factors were the prognostic nutrition index (p = 0.015), osteosarcopenia (p < 0.001), poorly differentiated adenocarcinoma (p = 0.004), perineural invasion (p = 0.002), and non-curability (p = 0.008), whereas the independent prognostic factors were prognostic nutrition index (p = 0.030), osteosarcopenia (p < 0.001), poorly differentiated adenocarcinoma (p = 0.007), lymphatic invasion (p = 0.018), and non-curability (p = 0.004). After PS matching, there was no significant difference in the variables between the patients with and without osteosarcopenia (n = 34 each). The 5-year DFS and OS after PS matching in patients with osteosarcopenia were significantly worse than in patients without osteosarcopenia (17.6% vs. 38.8%, p = 0.013 and 20.6% vs. 57.4%, p = 0.0005, respectively).
Conclusions: Preoperative osteosarcopenia could predict the DFS and OS of patients after resection for EBTC.
Keywords: Disease-free survival; Extrahepatic biliary tract cancer; Osteosarcopenia; Overall survival; Prognosis.
© 2023. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd.
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical